Video Credit: Texas SD-2 Senator Bob Hall.
While the argument about the efficacy and safety of vaccines is at the forefront of the C discussions, people are dying in hospitals, not because of the C, but because of hospital policy.
Vaccinated or not vaccinated, everyone testing C positive, deserves to be treated with the therapeutics (drugs) that work. Since no drug has formal FDA approval for C treatment (only emergency use authorization) all doctors should be free to use their medical judgement in using existing drugs, off label.
Unfortunately, most hospitals are refusing to allow their doctors to treat C patients with existing, safe, and effective drugs that many private practice doctors have been successfully using since soon after the initial C outbreak.
As more people become aware of the available treatments like, Ivermectin, hydroxoycholorine, and Budesonide and the success being achieved through outpatient private practice doctors, they are becoming frustrated when their loved one is hospitalized for C where hospital policies prohibit the use of theses safe and effective drugs.
The bottom line is, C patients, who make the mistake of seeking help from a hospital rather a private practice doctor, that are successfully using these drugs, are unnecessarily dying.
Fortunately, we now have surviving family members who are stepping-up to share their stories of abuse, neglect, and malpractice so that others are better equipped to protect their loved one that has the misfortune of being hospitalized.
I appreciate her courage in sharing her experience for the benefit of others.
Please share this FB post far and wide. Our previous videos are archived on our web site at www.SenatorBobHall.com
FIRST-HAND FAMILY COVID EXPERIENCE VIDEO:
Why is it that the United States has one of the best health care systems in the world, and yet is reporting one of the highest number of deaths per million in the world? Could it be our treatment choices? Could it be that most hospitalized C patients who die, do so because of hospital policies not of the C virus?
According to Dr. Bryan Ardis the United States has, one of the highest C death rates, per capita of any country in the world and the hospitals in the United States are the leading (if not the only) current users of a drug called Remdesivir to treat hospitalized C patients. In this interview, Dr. Ardis explains why he is appalled that Remdesivir is even being used to treat covid patient since it was pulled from use when, in a previous trial with Ebola patients, 49% of those taking the drug died. One of the well-known adverse side effects of the drug is irreparable kidney and liver damage.
One possible reason hospitals are quick to use Remdesivir is that the Federal Government pays hospitals an “add-on” payment for treatment of each C patient, regardless of whether they live or die. No other therapeutic such as Ivermectin, earns the hospital a bonus.
The World Health Organization has made a conditional recommendation against the U.S. gold standard C treatment drug, Remdesivir, citing that the evidence around the benefits and risks of an intervention are less certain. The National Institute of Health has acknowledged that its effectiveness has not been rigorously studied in clinical trials.
Those theoretical reasons, along with the FDA approval of Remesdivir, incentivized with increased government add-on payments (as much as a 40 percent increase) for the health care industries to use new, approved treatments for C, make it is easy to understand why it has become the primary drug of choice.
It always bears repeating, I am not a medical doctor. Medical studies, like statistics, can often be found to make any point you might want to make. My point in bringing these videos to you is to give you access to differing points of perspective than you may hear from mainstream media. Always check the information provided by me–or anyone else–for yourself. Do not just take my word for it.
Tune in as we discuss the studies that indicate that the top choice of drugs for treatment in the United States has had clinical studies ended early due to the adverse death rate in the studies and could possibly the primary reason that hospital death rate for C patients is so high.
KEY INFORMATION – LETS TALK FACTS VIDEO: